A world leader in the development of dendrimer products for pharmaceutical, life science, Starpharma Holdings Limited (ASX:SPL) revealed the completion of the phase 1 component of its phase 1/2 clinical trial for DEP® irinotecan.
The phase 1 clinical trial met its aim of evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy data including recommended dose for phase 2 trial.
Moreover, the company mentioned the commencement of phase 2 trial, which is for establishing anti-tumour activity and safety of DEP® irinotecan.
Share price of SPL stock climbed by 3.125% to $0.990, on 7 May 2020.